FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:581-589 March 2, 1995 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Buckley, D. A. PubMed Citation

Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1 to 3 percent of the world's population. The diagnosis is made on clinical grounds, although histologic examination of a skin-biopsy specimen may be helpful. Psoriasis is a disabling, though rarely life-threatening, disease with a social and economic impact that is underestimated by physicians and other health care providers. Recently, progress has been made in understanding the pathogenesis of psoriasis, and therapeutic advances are improving the care of even severely affected patients.

There are several types of psoriasis, including pustular, guttate, and arthritic variants. . . . [Full Text of this Article]

Risk Factors, Clinical Manifestations, and Natural History

Pathophysiologic Features

Treatment of Psoriasis

Topical Treatment

Emollients

Keratolytic Agents

Coal Tar

Anthralin

Corticosteroids

Calcipotriene

Phototherapy and Systemic Treatments

Phototherapy (Ultraviolet B Irradiation)

Photochemotherapy

Methotrexate

Etretinate

Systemic Corticosteroids

Cyclosporine

Therapeutic Strategies

Conclusions

Source Information

From St. John's Institute of Dermatology, St. Thomas's Hospital, United Medical and Dental Schools, Lambeth Palace Rd., London SE1 7EH, United Kingdom, where reprint requests should be addressed to Dr. Greaves.

References

Related Letters:

Treatment of Psoriasis
Buckley D. A., Rogers S., Wright R. A., Greaves M. W., Weinstein G. D.
Extract | Full Text  
N Engl J Med 1995; 333:258-259, Jul 27, 1995. Correspondence

This article has been cited by other articles:

• Chen, Y.-J., Wang, Y.-N., Chang, W.-C. (2007). ERK2-mediated C-terminal Serine Phosphorylation of p300 Is Vital to the Regulation of Epidermal Growth Factor-induced Keratin 16 Gene Expression. J. Biol. Chem. 282: 27215-27228 [Abstract] [Full Text]  
• Hassan, A. S., Simon, D., Simon, H.-U., Braathen, L. R., Yawalkar, N. (2007). Efalizumab-Associated Papular Psoriasis. Arch Dermatol 143: 900-906 [Abstract] [Full Text]  
• Coffey, G. P., Fox, J. A., Pippig, S., Palmieri, S., Reitz, B., Gonzales, M., Bakshi, A., Padilla-Eagar, J., Fielder, P. J. (2005). TISSUE DISTRIBUTION AND RECEPTOR-MEDIATED CLEARANCE OF ANTI-CD11A ANTIBODY IN MICE. Drug Metab. Dispos. 33: 623-629 [Abstract] [Full Text]  
• Bhagavathula, N., Nerusu, K. C., Fisher, G. J., Liu, G., Thakur, A. B., Gemmell, L., Kumar, S., Xu, Z. H., Hinton, P., Tsurushita, N., Landolfi, N. F., Voorhees, J. J., Varani, J. (2005). Amphiregulin and Epidermal Hyperplasia: Amphiregulin Is Required to Maintain the Psoriatic Phenotype of Human Skin Grafts on Severe Combined Immunodeficient Mice. Am. J. Pathol. 166: 1009-1016 [Abstract] [Full Text]  
• Spuls, P. I., Witkamp, L., Bossuyt, P. M. M., Bos, J. D. (2004). The Course of Chronic Plaque-Type Psoriasis in Placebo Groups of Randomized Controlled Studies. Arch Dermatol 140: 338-344 [Abstract] [Full Text]  
• Gordon, K. B., Papp, K. A., Hamilton, T. K., Walicke, P. A., Dummer, W., Li, N., Bresnahan, B. W., Menter, A. (2003). Efalizumab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial. JAMA 290: 3073-3080 [Abstract] [Full Text]  
• Gottlieb, A. B., Matheson, R. T., Lowe, N., Krueger, G. G., Kang, S., Goffe, B. S., Gaspari, A. A., Ling, M., Weinstein, G. D., Nayak, A., Gordon, K. B., Zitnik, R. (2003). A Randomized Trial of Etanercept as Monotherapy for Psoriasis. Arch Dermatol 139: 1627-1632 [Abstract] [Full Text]  
• Mahe, E., Bodemer, C., Pruszkowski, A., Teillac-Hamel, D., de Prost, Y. (2001). Cyclosporine in Childhood Psoriasis. Arch Dermatol 137: 1532-1533 [Full Text]  
• Ellis, C. N., Krueger, G. G., the Alefacept Clinical Study Group, (2001). Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes. NEJM 345: 248-255 [Abstract] [Full Text]  
• Granstein, R. D. (2001). New Treatments for Psoriasis. NEJM 345: 284-287 [Full Text]  
• Aractingi, S., Briand, N., Le Danff, C., Viguier, M., Bachelez, H., Michel, L., Dubertret, L., Carosella, E. D. (2001). HLA-G and NK Receptor Are Expressed in Psoriatic Skin : A Possible Pathway for Regulating Infiltrating T Cells?. Am. J. Pathol. 159: 71-77 [Abstract] [Full Text]  
• Duvic, M., Helekar, B., Schulz, C., Cho, M., DiSepio, D., Hager, C., DiMao, D., Hazarika, P., Jackson, B., Breuer-McHam, J., Young, J., Clayman, G., Lippman, S. M., Chandraratna, R. A. S., Robinson, N. A., Deucher, A., Eckert, R. L., Nagpal, S. (2000). Expression of a Retinoid-inducible Tumor Suppressor, Tazarotene-inducible Gene-3, Is Decreased in Psoriasis and Skin Cancer. Clin. Cancer Res. 6: 3249-3259 [Abstract] [Full Text]  
• Ellis, C. N., Varani, J., Fisher, G. J., Zeigler, M. E., Pershadsingh, H. A., Benson, S. C., Chi, Y., Kurtz, T. W. (2000). Troglitazone Improves Psoriasis and Normalizes Models of Proliferative Skin Disease: Ligands for Peroxisome Proliferator-Activated Receptor-{gamma} Inhibit Keratinocyte Proliferation. Arch Dermatol 136: 609-616 [Abstract] [Full Text]  
• Murphy, F. P., Coven, T. R., Burack, L. H., Gilleaudeau, P., Cardinale, I., Auerbach, R., Krueger, J. G. (1999). Clinical Clearing of Psoriasis by 6-Thioguanine Correlates With Cutaneous T-Cell Depletion via Apoptosis: Evidence for Selective Effects on Activated T Lymphocytes. Arch Dermatol 135: 1495-1502 [Abstract] [Full Text]  
• Lim, H. W., Anderson, T. F., Douglass, M., Koo, J., Lebwohl, M., Morison, W., Taylor, C., Zanolli, M., Chen, S., Garber, A. M. (1999). Cost-effectiveness of Methotrexate and Goeckerman Therapy: A Flawed Analysis. Arch Dermatol 135: 717-718 [Full Text]  
• Spuls, P. I., Bossuyt, P. M. M., van Everdingen, J. J. E., Witkamp, L., Bos, J. D. (1998). The Development of Practice Guidelines for the Treatment of Severe Plaque Form Psoriasis. Arch Dermatol 134: 1591-1596 [Abstract] [Full Text]  
• Coven, T. R., Murphy, F. P., Gilleaudeau, P., Cardinale, I., Krueger, J. G. (1998). Trimethylpsoralen Bath PUVA Is a Remittive Treatment for Psoriasis Vulgaris: Evidence That Epidermal Immunocytes Are Direct Therapeutic Targets. Arch Dermatol 134: 1263-1268 [Abstract] [Full Text]  
• Coven, T. R., Burack, L. H., Gilleaudeau, P., Keogh, M., Ozawa, M., Krueger, J. G. (1997). Narrowband UV-B Produces Superior Clinical and Histopathological Resolution of Moderate-to-Severe Psoriasis in Patients Compared With Broadband UV-B2. Arch Dermatol 133: 1514-1522 [Abstract]  
• Buckley, D. A., Rogers, S., Wright, R. A., Greaves, M. W., Weinstein, G. D. (1995). Treatment of Psoriasis. NEJM 333: 258-259 [Full Text]